Medicare Enrolled
Dr. Henry Rosevear, M.D.
Urology Physician · Troy, MI
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rosevear from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rosevear?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rosevear
Dr. Henry Rosevear is an urology physician in Troy, MI, with 19 years of NPI registration. Based on federal Medicare data, Dr. Rosevear performed 1,675 Medicare services across 1,199 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rosevear received a total of $2,650 from 37 pharmaceutical and/or device companies across 125 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rosevear is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 31% volume in MI
$2,650 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,675
Medicare services
Top 31% in MI for urology physician
1,199
Unique beneficiaries
$66
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~88 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
264 | $63 | $170 |
| Infectious disease DNA/RNA test A laboratory test that uses a specific technique to detect the genetic material of an organism. This method amplifies the target DNA or RNA to identify the presence of the organism. |
235 | $34 | $74 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
228 | $91 | $226 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
128 | $2 | $6 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
126 | $8 | $30 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
96 | $65 | $100 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
91 | $3 | $15 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
84 | $111 | $299 |
| Yeast/candida DNA test A laboratory test that uses an amplified probe technique to detect the presence of Candida species, a type of yeast, in a patient sample. |
73 | $34 | $73 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
66 | $106 | $189 |
| Ureteral stent insertion via endoscope A flexible tube is inserted into the ureter using an endoscope to keep the passage open and allow urine to flow from the kidney to the bladder. |
32 | $110 | $893 |
| Ureteral stone crushing with stent insertion An endoscope is used to break up a stone in the ureter, followed by the placement of a stent to keep the ureter open. |
28 | $348 | $1,316 |
| Complete ultrasound of retroperitoneum An ultrasound examination of the structures located behind the abdominal cavity. |
28 | $44 | $144 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
26 | $173 | $564 |
| Simple change of bladder tube | 22 | $61 | $204 |
| TB DNA amplification test A laboratory test that uses DNA amplification to detect the presence of tuberculosis bacteria in a sample. |
19 | $41 | $83 |
| Staphylococcus aureus DNA test A laboratory test that uses DNA amplification to detect the presence of Staphylococcus aureus bacteria in a sample. |
19 | $34 | $70 |
| Strep A nucleic acid amplification test A laboratory test that uses nucleic acid amplification to detect the presence of Group A Streptococcus bacteria. This method identifies the genetic material of the bacteria to determine if an infection is present. |
19 | $34 | $70 |
| Group B Strep DNA test A laboratory test that uses DNA amplification to detect the presence of Group B Streptococcus bacteria. |
19 | $34 | $70 |
| Endoscopic removal of foreign body, stone, or stent from urethra or bladder A procedure to remove a foreign object, stone, or stent from the urethra or bladder using an endoscope. The endoscope is a thin tube with a camera inserted into the urinary tract to locate and extract the item. |
17 | $252 | $780 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
15 | $43 | $107 |
| Transurethral prostate removal with electrocautery This procedure involves removing the prostate gland through the urethra using an endoscope and an electrocautery knife to control bleeding. |
14 | $572 | $1,899 |
| Bladder irrigation and/or instillation This procedure involves flushing the bladder with fluid to clear it or introducing medication directly into the bladder. |
13 | $51 | $148 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
13 | $88 | $178 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.6% high complexity
9.2% medium
86.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,650
Total received (2018-2024)
Avg $379/year across 7 years
Top 49% in MI for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
37
Companies
125
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,575 (97.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$64 (2.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12 (0.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$448
2023
$385
2022
$164
2021
$368
2020
$331
2019
$615
2018
$338
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
UROGEN PHARMA, INC.
$111
Sumitomo Pharma America, Inc.
$97
ABBVIE INC.
$87
Merck Sharp & Dohme LLC
$33
Astellas Pharma US Inc
$29
STERIS CORPORATION
$21
Endo USA, Inc.
$20
Calyxo, Inc.
$18
Tempus AI, Inc
$17
Myriad Genetic Laboratories, Inc.
$16
Top 3 companies account for 65.8% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$595
Medtronic USA, Inc.
$399
C. R. Bard, Inc. & Subsidiaries
$198
Myriad Genetic Laboratories, Inc.
$166
UROGEN PHARMA, INC.
$126
Sumitomo Pharma America, Inc.
$120
Medtronic, Inc.
$100
ABBVIE INC.
$99
AstraZeneca Pharmaceuticals LP
$78
Laborie Medical Technologies Corp.
$69
Coloplast Corp
$48
Bayer HealthCare Pharmaceuticals Inc.
$48
AbbVie Inc.
$43
Dendreon Pharmaceuticals LLC
$43
Allergan Inc.
$40
Intuitive Surgical, Inc.
$36
Myovant Sciences Inc.
$35
Merck Sharp & Dohme LLC
$33
Boston Scientific Corporation
$31
Ferring Pharmaceuticals Inc.
$28
Allergan, Inc.
$26
Janssen Biotech, Inc.
$26
Axonics, Inc.
$22
Blue Earth Diagnostics Limited
$21
STERIS CORPORATION
$21
Supernus Pharmaceuticals, Inc.
$20
Endo USA, Inc.
$20
Bard Access Systems, Inc.
$19
AngioDynamics, Inc.
$18
Calyxo, Inc.
$18
Novartis Pharmaceuticals Corporation
$17
Tempus AI, Inc
$17
180 Medical, Inc.
$16
Rochester Medical Corporation
$14
Bard Peripheral Vascular, Inc.
$14
Augmenix, Inc.
$13
PFIZER INC.
$12
Top 3 companies account for 45.0% of all-time payments
Associated products mentioned in payments ›
AFINITOR · Altis · Axumin · BOTOX · BOTOX THERAPEUTIC · Bulkamid · CVAC ASPIRATION SYSTEM · Da Vinci Surgical System · Erleada · FIRMAGON · GEMTESA · GIA · INTERSTIM · JELMYTO · KEYTRUDA · LUPRON DEPOT · MYRBETRIQ · MYRISK · Myrbetriq · NANOKNIFE · NOCDURNA · ORGOVYX · PROLARIS · PROVENGE · Prolaris · SpaceOAR · SpaceOAR VUE System - 10mL · TLANDO · Uretero1 · VENOVO · XIAFLEX · XTANDI · Xofigo · Xtandi
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Urology physicians within 10 mi
172
Per 100K population
13.5
County median income
$95,296
Nearest hospital
BEAUMONT HOSPITAL ROYAL OAK
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rosevear is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rosevear experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Rosevear performed 264 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rosevear receive payments from pharmaceutical companies?
Yes. Dr. Rosevear received a total of $2,650 from 37 companies across 125 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rosevear's costs compare to other urology physicians in Troy?
Dr. Rosevear's average Medicare payment per service is $66. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rosevear) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Troy
Browse urology physicians in Troy ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in MI
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in MI
Which MI urology physicians receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Medtronic USA, Inc. Payments to Doctors
See all physicians who received payments from Medtronic USA, Inc.
By company
C. R. Bard, Inc. & Subsidiaries Payments to Doctors
See all physicians who received payments from C. R. Bard, Inc. & Subsidiaries.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology